Accelerate Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:05 pm EDT
Share
Accelerate Diagnostics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 2.92 million compared to USD 3.86 million a year ago. Net loss was USD 25.98 million compared to USD 18.52 million a year ago. Basic loss per share from continuing operations was USD 2.36 compared to USD 2.43 a year ago.
For the six months, sales was USD 5.73 million compared to USD 6.82 million a year ago. Net loss was USD 42.78 million compared to USD 31.99 million a year ago. Basic loss per share from continuing operations was USD 4.11 compared to USD 4.44 a year ago.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.